Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). In conjunction with immunosuppressive therapy, VX-880 produced robust restoration of islet cell function on Day 90 in the first patient in its Phase 1/2 clinical trial.... Read more about A new therapy for treating Type 1 diabetes

CALL FOR PROPOSALS

2021 HSCI MUSCULOSKELETAL DISEASE PROGRAM PILOT GRANTS

AWARD AMOUNT
Up to $100,000 for entire project period
Project period not to exceed two years
POSTED DATE
Friday, October 8, 2021
DEADLINE FOR APPLICATION
Friday, November 12, 2021
ANTICIPATED AWARD DATE
January 1, 2022
 

The Harvard Stem Cell Institute (HSCI) Musculoskeletal (MSK) Disease Program invites applications for pilot grant funding. The purpose of this program is to provide funding for innovative projects in the field of musculoskeletal stem cell and regenerative biology. HSCI strongly encourages proposals with a translational focus, or which are otherwise poised to accelerate the development of new stem cell-based therapies or cures for musculoskeletal injuries or disease. However, proposals at all stages of development are welcome, as are proposals that encompass a collaboration between two MSK labs where at least one of the labs is member of the HSCI. The HSCI MSK Program intends to award up to two grants in response to this call for proposals, contingent upon the number and quality of the proposals received, as well as the availability of HSCI MSK Disease Program funds.... Read more about Call for Proposals: 2021 HSCI Musculoskeletal Disease Program Pilot Grants

A group of researchers, led by HSCI Co-Director David Scadden, MD, has shown that bone cells pass packets of genetic material directly to bone progenitors, increasing blood production and stimulating the immune cells necessary to fight infection. ... Read more about A new signaling system for blood regeneration

A Harvard Stem Cell Institute (HSCI) led collaboration developed a new macroencapsulation device (MED) that protects the insulin-producing cells of the pancreas and enhances their survival with improved nutrient supply. ... Read more about Bioartificial device offers potential for treatment of Type 1 diabetes

New insight into the workings of the hormone irisin shows it has the ability to spur the cognitive benefits of exercise, holding promise for treating cognitive decline in Alzheimer's disease, a HSCI led team at Massachusetts General Hospital have found. ... Read more about The hormone irisin is found to confer benefits of exercise on cognitive function

Researchers at Massachusetts General Hospital (MGH) led by Harvard Stem Cell Institute Principal Faculty Harald C. Ott M.D. have generated the embryonic cells that support early heart development.

... Read more about Researchers generate protective embryonic heart cells

HSCI researchers led by Tracy Young-Pearse, Ph.D., have developed a method to examine living brain cells and predict the rate of Alzheimer’s disease progression and cognitive decline.

... Read more about New brain model sheds patient-specific light on Alzheimer’s disease

HSCI researchers use patient-derived motor neurons to screen for clinically relevant targets

Harvard and Broad researchers combine single-cell genomic technologies to map the mouse cortex

CALL FOR PROPOSALS

FALL 2021 HSCI COLLABORATIVE SEED GRANTS

AWARD AMOUNT
$100,000 per project per year for up to two years
POSTED DATE
Monday, June 21, 2021
DEADLINE FOR APPLICATION
Friday, September 17, 2021
ANTICIPATED AWARD DATE
Monday, November 1, 2021
 

The Harvard Stem Cell Institute (HSCI) invites applications for seed grant funding for its Fall 2021 cycle.

The purpose of this program is to provide funding for innovative projects in the field of stem cell and regenerative biology that are a collaboration between two labs. HSCI strongly encourages proposals with a translational focus, or which are otherwise poised to accelerate the development of new stem cell-based therapies or cures. However, proposals at all stages of development are welcome. The HSCI intends to award up to five grants in response to this call for proposals, contingent upon the number and quality of the proposals received, as well as the availability of HSCI funds.... Read more about Call for Proposals: 2021 Fall HSCI Collaborative Seed Grants

HSCI researchers identify mechanism with therapeutic potential for anemia

HSCI researchers identify new potential target for obesity therapy

HSCI researchers identify mechanism for regenerating hair follicle stem cells